Intraocular Lens Suture Needle Pharmaceutical Cataract Kit Spectacle Lens Hearing Aid
   

  AUROSIL

 



  • Greater stability

  • Reduced emulsification due to a high degree of purification and low level of reactive -OH end groups

  • Less tissue impregnation

  • Subject to all physical and chemical analysis (H-NMR spectral test, gel permeation chromatography study and gas chromatography) to ensure purity level

  • Low level of catalyst impurities minimize the risks of interactions with the ocular environment

  • Quality product with a proven track record

 


 High Quality, Purified Silicone Oil

A Tamponade to treat Complex Retinal Detachments

DESCRIPTION
AUROSIL is fractionated, purified, sterile and apyrogenic silicone oil designed for prolonged tamponade after surgical treatment for severe retinal detachment.

CHARACTERISTICS
Viscosity (at 25°C) : 1000 cSt ± 50 cSt
Refractive index (at 25°C) : 1.4013 – 1.4053
Specific Gravity (at 30°C) : 0.9740 ± 0.001
Average Molecular Weight (daltons) : 44,000 ±1000
Poly Dispersion Index : 2.5
Toxic Residue : Nil
Content of -OH-end groups : <70 ppm

INDICATIONS
Retinal detachment with giant tear, retinal detachment with proliferative vitreo retinopathy (PVR), proliferative diabetic retinopathy (PDR) and traumatic retinal detachment.

CONTRAINDICATION
Pseudophakic patients with silicone intraocular lens (silicone oil can chemically interact and opacify silicone elastomers).

PRECAUTIONS
As with any surgical procedure, posterior segment surgery using AUROSIL presents risks which the surgeon must evaluate.
Do not resterilize. Single use product only. Do not use if packaging that ensures sterility is damaged. Do not use after expiry date.

DIRECTIONS
In aseptic conditions decant the contents of the bottle into a sterile syringe. Place the syringe in a syringe driver in order to facilitate the injection. Plug in the infusion terminal to the tip of the syringe. Inject slowly.

During withdrawal, avoid leaving silicone bubbles in the vitreo-retinal cavity. Once AUROSIL is removed from the patient's eye it should be treated as any human biological product.

ADVERSE REACTIONS
The most common adverse reactions include cataract, anterior chamber oil migration, keratopathy and glaucoma. Other adverse reactions include optic nerve atrophy, rubeosis iritis, temporary IOP increase, macular pucker, vitreous hemorrhage, phthisis, traction detachment, angle block, subretinal strands, retinal rupture, endophthalmitis,
subretinal silicone oil, choroidal detachment, aniridia and cystoid macular edema. Opacification of silicone IOL has been reported (in-vitro).

ADMIXTURE INCOMPATIBILITY
Do not admix with any other substance prior to injection

STORAGE
Store between 2ºC and 35ºC.

SUPPLY
10 ml vial in a sterile pouch

   

Top

back